Literature DB >> 34870951

CORR Insights®: Is Chemotherapy Associated with Improved Overall Survival in Patients with Dedifferentiated Chondrosarcoma? A SEER Database Analysis.

Drake G LeBrun1.   

Abstract

Entities:  

Mesh：

Year:  2022        PMID： 34870951      PMCID： PMC8923591          DOI： 10.1097/CORR.0000000000002066

Source DB:  PubMed          Journal:  Clin Orthop Relat Res        ISSN： 0009-921X            Impact factor:   4.755


× No keyword cloud information.
  17 in total

1.  Risk factors for survival and local control in chondrosarcoma of bone.

Authors:  F Fiorenza; A Abudu; R J Grimer; S R Carter; R M Tillman; K Ayoub; D C Mangham; A M Davies
Journal:  J Bone Joint Surg Br       Date:  2002-01

2.  Dedifferentiated chondrosarcoma: A survival analysis of 159 cases from the SEER database (2001-2011).

Authors:  Patrick K Strotman; Taylor J Reif; Stephanie A Kliethermes; Jasmin K Sandhu; Lukas M Nystrom
Journal:  J Surg Oncol       Date:  2017-04-18       Impact factor: 3.454

Review 3.  Harnessing the immune system against cancer: current immunotherapy approaches and therapeutic targets.

Authors:  Aswathy R Devan; Bhagyalakshmi Nair; Ayana R Kumar; Balachandran S Vinod; Lekshmi R Nath
Journal:  Mol Biol Rep       Date:  2021-10-20       Impact factor: 2.316

4.  Results of a prospective phase 2 study of pazopanib in patients with surgically unresectable or metastatic chondrosarcoma.

Authors:  Warren Chow; Paul Frankel; Chris Ruel; Dejka M Araujo; Mohammed Milhem; Scott Okuno; Lee Hartner; Samir Undevia; Arthur Staddon
Journal:  Cancer       Date:  2019-09-11       Impact factor: 6.860

5.  Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial.

Authors:  Hussein A Tawbi; Melissa Burgess; Vanessa Bolejack; Brian A Van Tine; Scott M Schuetze; James Hu; Sandra D'Angelo; Steven Attia; Richard F Riedel; Dennis A Priebat; Sujana Movva; Lara E Davis; Scott H Okuno; Damon R Reed; John Crowley; Lisa H Butterfield; Ruth Salazar; Jaime Rodriguez-Canales; Alexander J Lazar; Ignacio I Wistuba; Laurence H Baker; Robert G Maki; Denise Reinke; Shreyaskumar Patel
Journal:  Lancet Oncol       Date:  2017-10-04       Impact factor: 41.316

Review 6.  Chondrosarcoma: An overview of clinical behavior, molecular mechanisms mediated drug resistance and potential therapeutic targets.

Authors:  Elahe Nazeri; Mohammad Gouran Savadkoohi; Keivan Majidzadeh-A; Rezvan Esmaeili
Journal:  Crit Rev Oncol Hematol       Date:  2018-09-12       Impact factor: 6.312

7.  Response to anti-PD1 therapy with nivolumab in metastatic sarcomas.

Authors:  L Paoluzzi; A Cacavio; M Ghesani; A Karambelkar; A Rapkiewicz; J Weber; G Rosen
Journal:  Clin Sarcoma Res       Date:  2016-12-30

Review 8.  Immunotherapy for Chordoma and Chondrosarcoma: Current Evidence.

Authors:  Jeffrey I Traylor; Mark N Pernik; Aaron R Plitt; Michael Lim; Tomas Garzon-Muvdi
Journal:  Cancers (Basel)       Date:  2021-05-17       Impact factor: 6.639

9.  Clinical outcome for patients with dedifferentiated chondrosarcoma: a report of 9 cases at a single institute.

Authors:  Kazuya Yokota; Akio Sakamoto; Yoshihiro Matsumoto; Shuichi Matsuda; Katsumi Harimaya; Yoshinao Oda; Yukihide Iwamoto
Journal:  J Orthop Surg Res       Date:  2012-12-10       Impact factor: 2.359

Review 10.  The Identification of Prognostic Factors and Survival Statistics of Conventional Central Chondrosarcoma.

Authors:  Sjoerd P F T Nota; Yvonne Braun; Joseph H Schwab; C Niek van Dijk; Jos A M Bramer
Journal:  Sarcoma       Date:  2015-11-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.